Targeted Oncology· @TargetedOnc · X·· 14 小时前评分70
正文 · 原文
DeLLphi-305 raises a real-world challenge:
CRS occurred in 49.6% with tarlatamab + durvalumab, although grade ≥3 CRS was only 0.4%. ICANS: 1.1%.
Can community oncology safely deliver this regimen?
Monitoring, resources and patient access will be critical. #ESMO26
91 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Targeted Oncology · x.com